The domain within your query sequence starts at position 243 and ends at position 755; the E-value for the Caldesmon domain shown below is 3.8e-144.

EQDMEEIARRKKMGEEERERAEAERLRLEVEGQEQERIKAEQDRKLAEERARVEAEQKAA
AEERERREAEERERREAEERERREAEERAEQARIQEEQRRVAEAQKKAKAEEEEKARIEE
QRQKQQLEEQRSEKREAKDKGEKGAEKADRKGVNEREAPDDRLQTAVPKTQEEEKGVKGQ
AQRQKPRDDKPAFRKEEIKDEKIKKDKEPKEEVKSFLDRKKGFTEVKAQNGEFMTHKLKQ
TENAFSRSGGRASGDKEAEGAPQVEAGKRLEELRRRRGETENEEFEKLKQKQQEAALELE
ELKKKREERRKVLEEEEQRRKQEEADRKAREEEEKRRLKEEIERRRAEAAEKRQKMPEDG
LSEDKKPFKCFTPKGSSLKIEERAEFLNKSVQKSGVRSTHQAAVVSKIDSRLEQYTNAIE
GTKASKPMKPAASDLPVPAEGVRNIKSMWEKGSVFSAPSASGTPNKETAGLKVGVSSRIN
EWLTKSPDGNKSPAPKPSDLRPGDVSGKRNLWE

Caldesmon

Caldesmon
PFAM accession number:PF02029
Interpro abstract (IPR006018):

This group of proteins includes two protein families: caldesmon and lymphocyte specific protein.

Caldesmon (CDM) is an actin- and myosin-binding protein implicated in the regulation of actomyosin interactions in smooth muscle and non-muscle cells, possibly acting as a bridge between myosin and actin filaments [ (PUBMED:1555769) ]. CDM is believed to be an elongated molecule, with an N-terminal myosin/calmodulin- binding domain and a C-terminal tropomyosin/actin/calmodulin-binding domain, separated by a 40nm-long central helix [ (PUBMED:1555769) ].

A high-molecular-weight form of CDM is predominantly expressed in smooth muscles, while a low-molecular-weight form is widely distributed in non- muscle tissues and cells (the protein is not expressed in skeletal muscle or heart).

This is a PFAM domain. For full annotation and more information, please see the PFAM entry Caldesmon